Literature DB >> 30719677

Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation.

Oliver S Chow1, Sujata Patil2, Metin Keskin2, J Joshua Smith2, Maria Widmar2, David D Smith3, Karin Avila2, Jinru Shia2, Peiguo Chu4, Julio Garcia-Aguilar5.   

Abstract

BACKGROUND: Pathologic complete response (pCR) is associated with better prognosis and guides management for patients with advanced rectal cancer. Response rates vary between series for unclear reasons. We examine whether the thoroughness of pathologic assessment explains differences in pCR rates.
METHODS: We retrospectively reviewed pathology reports from patients with stage II/III rectal cancer who underwent chemoradiation and resection in a prospective, multicenter trial. We utilized a novel measure for the thoroughness of pathologic assessment by dividing residual tumor size by the number of cassettes evaluated (tumor size to cassette ratio, TSCR), and evaluated whether TSCR is associated with pCR. We validated our findings using a separate cohort.
RESULTS: From the trial cohort, 71 of 247 (29%) patients achieved pCR. The pCR rate ranged from 0 to 45% and mean TSCR ranged 0.29 to 0.87 across 12 institutions. Within each institution, a lower TSCR was associated with pCR, demonstrating a higher degree of thoroughness used for tumors that achieved pCR. Moreover, across all samples, low TSCR was independently associated with pCR on multivariable analysis. This finding was corroborated in a separate cohort of 201 tumors evaluated by five pathologists; each pathologist had a lower mean TSCR for pCR calls compared with non-pCR calls. However, the mean TSCR for an institution was not associated with its overall pCR rate.
CONCLUSIONS: Pathologists assess rectal cancers that have responded significantly to neoadjuvant therapy more thoroughly. Thoroughness does not appear to explain differences in pCR rates between institutions. Our results suggest pCR is not a sampling artifact.

Entities:  

Keywords:  Chemoradiotherapy; RECIST; Rectal cancer; Residual tumor; Surgical pathology

Mesh:

Substances:

Year:  2019        PMID: 30719677      PMCID: PMC6430657          DOI: 10.1007/s11605-019-04119-x

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  18 in total

1.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

2.  Recommendations for the reporting of surgically resected specimens of colorectal carcinoma.

Authors:  Jeremy R Jass; Michael J O'Brien; Robert H Riddell; Dale C Snover
Journal:  Hum Pathol       Date:  2007-02-01       Impact factor: 3.466

3.  Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).

Authors:  Alice Dewdney; David Cunningham; Josep Tabernero; Jaume Capdevila; Bengt Glimelius; Andres Cervantes; Diana Tait; Gina Brown; Andrew Wotherspoon; David Gonzalez de Castro; Yu Jo Chua; Rachel Wong; Yolanda Barbachano; Jacqueline Oates; Ian Chau
Journal:  J Clin Oncol       Date:  2012-04-02       Impact factor: 44.544

4.  Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer.

Authors:  J V Schou; F O Larsen; L Rasch; D Linnemann; J Langhoff; E Høgdall; D L Nielsen; K Vistisen; A Fromm; B V Jensen
Journal:  Ann Oncol       Date:  2012-04-02       Impact factor: 32.976

5.  Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.

Authors:  Claus Rödel; Torsten Liersch; Heinz Becker; Rainer Fietkau; Werner Hohenberger; Torsten Hothorn; Ullrich Graeven; Dirk Arnold; Marga Lang-Welzenbach; Hans-Rudolf Raab; Heiko Sülberg; Christian Wittekind; Sergej Potapov; Ludger Staib; Clemens Hess; Karin Weigang-Köhler; Gerhard G Grabenbauer; Hans Hoffmanns; Fritz Lindemann; Anke Schlenska-Lange; Gunnar Folprecht; Rolf Sauer
Journal:  Lancet Oncol       Date:  2012-05-23       Impact factor: 41.316

6.  Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence.

Authors:  Luiz Felipe de Campos-Lobato; Luca Stocchi; Andre da Luz Moreira; Daniel Geisler; David W Dietz; Ian C Lavery; Victor W Fazio; Matthew F Kalady
Journal:  Ann Surg Oncol       Date:  2011-01-05       Impact factor: 5.344

7.  Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.

Authors:  Carlo Aschele; Luca Cionini; Sara Lonardi; Carmine Pinto; Stefano Cordio; Gerardo Rosati; Salvatore Artale; Angiolo Tagliagambe; Giovanni Ambrosini; Paola Rosetti; Andrea Bonetti; Maria Emanuela Negru; Maria Chiara Tronconi; Gabriele Luppi; Giovanni Silvano; Domenico Cristiano Corsi; Anna Maria Bochicchio; Germana Chiaulon; Maurizio Gallo; Luca Boni
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

8.  Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data.

Authors:  Monique Maas; Patty J Nelemans; Vincenzo Valentini; Prajnan Das; Claus Rödel; Li-Jen Kuo; Felipe A Calvo; Julio García-Aguilar; Rob Glynne-Jones; Karin Haustermans; Mohammed Mohiuddin; Salvatore Pucciarelli; William Small; Javier Suárez; George Theodoropoulos; Sebastiano Biondo; Regina G H Beets-Tan; Geerard L Beets
Journal:  Lancet Oncol       Date:  2010-08-06       Impact factor: 41.316

9.  KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.

Authors:  Jochen Gaedcke; Marian Grade; Klaus Jung; Markus Schirmer; Peter Jo; Christoph Obermeyer; Hendrik A Wolff; Markus K Herrmann; Tim Beissbarth; Heinz Becker; Thomas Ried; Michael Ghadimi
Journal:  Radiother Oncol       Date:  2009-11-11       Impact factor: 6.280

10.  Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.

Authors:  Yu Jo Chua; Yolanda Barbachano; David Cunningham; Jacqui R Oates; Gina Brown; Andrew Wotherspoon; Diana Tait; Alison Massey; Niall C Tebbutt; Ian Chau
Journal:  Lancet Oncol       Date:  2010-01-25       Impact factor: 41.316

View more
  1 in total

1.  Vascular calcification and response to neoadjuvant therapy in locally advanced rectal cancer: an exploratory study.

Authors:  Katrina A Knight; Ioanna Drami; Donald C McMillan; Paul G Horgan; James H Park; John T Jenkins; Campbell S D Roxburgh
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-12       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.